JPWO2020071554A1 - がん幹細胞特異的抗体 - Google Patents

がん幹細胞特異的抗体 Download PDF

Info

Publication number
JPWO2020071554A1
JPWO2020071554A1 JP2020551131A JP2020551131A JPWO2020071554A1 JP WO2020071554 A1 JPWO2020071554 A1 JP WO2020071554A1 JP 2020551131 A JP2020551131 A JP 2020551131A JP 2020551131 A JP2020551131 A JP 2020551131A JP WO2020071554 A1 JPWO2020071554 A1 JP WO2020071554A1
Authority
JP
Japan
Prior art keywords
antibody
antigen
cancer
seq
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551131A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020071554A5 (https=
Inventor
智英 塚原
智英 塚原
俊彦 鳥越
俊彦 鳥越
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapporo Medical University
Original Assignee
Sapporo Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapporo Medical University filed Critical Sapporo Medical University
Publication of JPWO2020071554A1 publication Critical patent/JPWO2020071554A1/ja
Publication of JPWO2020071554A5 publication Critical patent/JPWO2020071554A5/ja
Priority to JP2024067659A priority Critical patent/JP2024144409A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020551131A 2018-10-05 2019-10-04 がん幹細胞特異的抗体 Pending JPWO2020071554A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067659A JP2024144409A (ja) 2018-10-05 2024-04-18 がん幹細胞特異的抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018189834 2018-10-05
JP2018189834 2018-10-05
PCT/JP2019/039400 WO2020071554A1 (ja) 2018-10-05 2019-10-04 がん幹細胞特異的抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067659A Division JP2024144409A (ja) 2018-10-05 2024-04-18 がん幹細胞特異的抗体

Publications (2)

Publication Number Publication Date
JPWO2020071554A1 true JPWO2020071554A1 (ja) 2021-09-09
JPWO2020071554A5 JPWO2020071554A5 (https=) 2022-10-14

Family

ID=70055296

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551131A Pending JPWO2020071554A1 (ja) 2018-10-05 2019-10-04 がん幹細胞特異的抗体
JP2024067659A Pending JP2024144409A (ja) 2018-10-05 2024-04-18 がん幹細胞特異的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067659A Pending JP2024144409A (ja) 2018-10-05 2024-04-18 がん幹細胞特異的抗体

Country Status (4)

Country Link
US (1) US20220033513A1 (https=)
EP (1) EP3862366A4 (https=)
JP (2) JPWO2020071554A1 (https=)
WO (1) WO2020071554A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010068A2 (en) * 2021-07-28 2023-02-02 Cartesian Therapeutics, Inc. Multiprotein-engineered cells secreting a multispecific antibody
WO2023204290A1 (ja) * 2022-04-21 2023-10-26 愛知県 多重特異性ナノ粒子
TW202528342A (zh) * 2023-09-01 2025-07-16 日商小野藥品工業股份有限公司 Ｈｌａ／癌症抗原ｐｖｔ１衍生胜肽複合體特異性抗體

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521053A (ja) * 1998-07-28 2002-07-16 マイクロメット アーゲー ヘテロミニ体
WO2010050190A1 (ja) * 2008-10-27 2010-05-06 北海道公立大学法人札幌医科大学 がん幹細胞分子マーカー
WO2014153002A1 (en) * 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
JP2014529600A (ja) * 2011-08-23 2014-11-13 ロシュ グリクアート アーゲー Ｔ細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法
WO2015050259A1 (ja) * 2013-10-03 2015-04-09 大日本住友製薬株式会社 腫瘍抗原ペプチド
WO2016047715A1 (ja) * 2014-09-24 2016-03-31 北海道公立大学法人札幌医科大学 腫瘍抗原ペプチド
JP2016516049A (ja) * 2013-03-15 2016-06-02 メモリアル スローン−ケタリング キャンサー センター 多量体化技術

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521053A (ja) * 1998-07-28 2002-07-16 マイクロメット アーゲー ヘテロミニ体
WO2010050190A1 (ja) * 2008-10-27 2010-05-06 北海道公立大学法人札幌医科大学 がん幹細胞分子マーカー
JP2014529600A (ja) * 2011-08-23 2014-11-13 ロシュ グリクアート アーゲー Ｔ細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法
WO2014153002A1 (en) * 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
JP2016516049A (ja) * 2013-03-15 2016-06-02 メモリアル スローン−ケタリング キャンサー センター 多量体化技術
WO2015050259A1 (ja) * 2013-10-03 2015-04-09 大日本住友製薬株式会社 腫瘍抗原ペプチド
WO2016047715A1 (ja) * 2014-09-24 2016-03-31 北海道公立大学法人札幌医科大学 腫瘍抗原ペプチド

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. 12, no. 3, JPN6019049028, 2017, pages 0171460 - 1, ISSN: 0005142639 *
日本整形外科学会雑誌, vol. 92, no. 8, JPN6019049021, 30 August 2018 (2018-08-30), pages 1942 - 2, ISSN: 0005142636 *
日本病理学会会誌, vol. 107, no. 1, JPN6019049023, 26 April 2018 (2018-04-26), pages 397 - 1, ISSN: 0005142637 *
日本病理学会会誌, vol. 107, no. 1, JPN6019049025, 26 April 2018 (2018-04-26), pages 522 - 36, ISSN: 0005142638 *

Also Published As

Publication number Publication date
EP3862366A1 (en) 2021-08-11
US20220033513A1 (en) 2022-02-03
JP2024144409A (ja) 2024-10-11
EP3862366A4 (en) 2022-06-29
WO2020071554A1 (ja) 2020-04-09

Similar Documents

Publication Publication Date Title
US9845362B2 (en) Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
JP2025032089A (ja) 腫瘍微小環境を標的とするキメラ抗原受容体
EP3241561B1 (en) Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
US11207393B2 (en) Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
US11385233B2 (en) Methods of depleting malignant T-cells
AU2018250336A1 (en) Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
JP2024144409A (ja) がん幹細胞特異的抗体
JP7308190B2 (ja) 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
JP2018525421A (ja) Ｃｄ４７遮断及び免疫同時刺激アゴニストを用いた標的細胞の枯渇亢進
JP2013535963A (ja) Ｍｈｃクラスｉｉと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
CN114340659B (zh) 联合治疗
US20120027674A1 (en) Il-18 receptor as a novel target of regulatory t cells in cancer
JP5566374B2 (ja) 形質細胞の腫瘍性増殖をきたす疾患の治療薬
JP2022528238A (ja) がん療法で使用するためのセマフォリン－４ｄアンタゴニスト
US11554181B2 (en) Tumor specific antibody conjugates and uses therefor
WO2025047920A1 (ja) Ｈｌａ／がん抗原ｐｖｔ１由来ペプチド複合体特異的抗体
US12605469B2 (en) Tumor specific antibody conjugates and uses therefor
Dias Clinical and immunological characterization of naturally occurring canine lymphoma: development and application of engineered recombinant antibodies for diagnosis and treatment
WO2021045728A1 (en) Tumor specific antibody conjugates and uses therefor
RU2803148C2 (ru) Противоопухолевое средство и способ его оценки
Jalil The Development Of Multivalent Nano-Self Peptides As Antagonists For Antibody-Dependent Macrophage Phagocytosis
HK40073153B (zh) 联合治疗
HK40000286A (en) Gene products differentially expressed in tumors and their uses

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240418

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240527

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240809